Related Experiment Video

Updated: Jun 28, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.5K

Exploring FGFR signaling inhibition as a promising approach in breast cancer treatment

Yan Peng1, Pengfei Zhang2, Wuxuan Mei3

  • 1Department of Obstetrics, Shenzhen Longhua District Central Hospital, Shenzhen 518110, China.

International Journal of Biological Macromolecules
|April 12, 2024
PubMed

Insights

Targeted therapies inhibiting the fibroblast growth factor receptor (FGFR) pathway show promise for breast cancer treatment. This review explores FGFR aberrations, targeted inhibitors, and managing treatment toxicity in breast carcinoma.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Fibroblast growth factor receptors (FGFR) pathway is implicated in breast carcinoma pathogenesis.
  • Precision medicine leverages targeted therapies for cancer treatment.
  • FGFR signaling aberrations drive tumor progression in various malignancies.

Purpose of the Study:

  • To review FGFR pathway aberrations and their functional roles in breast cancer.
  • To explore targeted therapeutic strategies for breast cancer patients with FGFR alterations.
  • To discuss the management of toxicities associated with FGFR inhibitors.

Main Methods:

  • Literature review of studies on FGFR pathway in breast cancer.
  • Analysis of clinical data on FGFR inhibitors.
  • Examination of preclinical and clinical research on targeted therapies.

Main Results:

  • FGFR pathway alterations are key drivers in a subset of breast cancers.
  • Numerous FGFR inhibitors have been developed, showing efficacy in preclinical and clinical settings.
  • Management strategies for FGFR inhibitor toxicities are crucial for patient care.

Conclusions:

  • Targeted inhibition of the FGFR pathway represents a promising therapeutic avenue for breast cancer.
  • Understanding FGFR aberrations is critical for selecting appropriate patients for targeted therapy.
  • Continued research into novel FGFR inhibitors and combination therapies is warranted.
Keywords:
AmplificationBreast cancerFGFRFGFR inhibitorMutation

More Related Videos

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation08:48

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

8.3K
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K